Total Payments
$358,500
2024 Payments
$22,208
Companies
13
Transactions
155
Medicare Patients
1,567
Medicare Billing
$350,738
Payment Breakdown by Category
Research$147,058 (41.0%)
Consulting$119,300 (33.3%)
Other$84,224 (23.5%)
Travel$4,726 (1.3%)
Food & Beverage$2,917 (0.8%)
Education$274.74 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $147,058 | 2 | 41.0% |
| Consulting Fee | $119,300 | 32 | 33.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $84,224 | 37 | 23.5% |
| Travel and Lodging | $4,726 | 16 | 1.3% |
| Food and Beverage | $2,917 | 67 | 0.8% |
| Education | $274.74 | 1 | 0.1% |
Payments by Type
General
$211,442
153 transactions
Research
$147,058
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $153,259 | 107 | $0 (2024) |
| ABBVIE INC. | $140,815 | 4 | $0 (2023) |
| Eli Lilly and Company | $20,528 | 14 | $0 (2024) |
| Allergan, Inc. | $16,624 | 15 | $0 (2022) |
| Aclaris Therapeutics, Inc. | $10,248 | 1 | $0 (2018) |
| Janssen Scientific Affairs, LLC | $6,075 | 2 | $0 (2024) |
| PFIZER INC. | $5,719 | 5 | $0 (2024) |
| Avita Medical Americas, LLC | $3,556 | 1 | $0 (2023) |
| Galderma Laboratories, L.P. | $1,575 | 1 | $0 (2021) |
| LEO Pharma Inc. | $42.84 | 2 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $22,208 | 25 | Incyte Corporation ($15,459) |
| 2023 | $222,934 | 54 | ABBVIE INC. ($140,815) |
| 2022 | $71,286 | 44 | Incyte Corporation ($61,852) |
| 2021 | $11,375 | 7 | Incyte Corporation ($5,573) |
| 2020 | $7,966 | 5 | PFIZER INC. ($5,670) |
| 2019 | $9,231 | 11 | Eli Lilly and Company ($7,587) |
| 2018 | $13,437 | 5 | Aclaris Therapeutics, Inc. ($10,248) |
| 2017 | $62.91 | 4 | Allergan Inc. ($34.76) |
All Payment Transactions
155 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Integra LifeSciences Corporation | ACCLARENT AERA (Device), INSPIRA AIR, TruDi Probe | Food and Beverage | In-kind items and services | $17.26 | General |
| Category: ENT | ||||||
| 11/05/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $14.38 | General |
| Category: DERMATOLOGY | ||||||
| 10/04/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $3.78 | General |
| Category: Dermatology | ||||||
| 09/23/2024 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $3,200.00 | General |
| 08/14/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $22.41 | General |
| Category: Dermatology | ||||||
| 06/17/2024 | Incyte Corporation | OPZELURA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,200.00 | General |
| Category: Dermatology | ||||||
| 05/21/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $27.20 | General |
| Category: Dermatology | ||||||
| 03/28/2024 | Eli Lilly and Company | OLUMIANT (Drug) | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
| Category: Immunology | ||||||
| 03/21/2024 | Incyte Corporation | OPZELURA (Drug) | Consulting Fee | Cash or cash equivalent | $4,800.00 | General |
| Category: Dermatology | ||||||
| 03/21/2024 | Incyte Corporation | OPZELURA (Drug) | Consulting Fee | Cash or cash equivalent | $4,400.00 | General |
| Category: Dermatology | ||||||
| 03/15/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $4.19 | General |
| Category: Dermatology | ||||||
| 03/01/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $17.16 | General |
| Category: DERMATOLOGY | ||||||
| 02/13/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| Category: Immunology | ||||||
| 02/12/2024 | Incyte Corporation | OPZELURA (Drug) | Travel and Lodging | Cash or cash equivalent | $447.00 | General |
| Category: Dermatology | ||||||
| 02/12/2024 | Incyte Corporation | OPZELURA (Drug) | Travel and Lodging | Cash or cash equivalent | $367.26 | General |
| Category: Dermatology | ||||||
| 02/12/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $56.00 | General |
| Category: Dermatology | ||||||
| 02/12/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $50.00 | General |
| Category: Dermatology | ||||||
| 02/12/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $49.31 | General |
| Category: Dermatology | ||||||
| 02/12/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $25.00 | General |
| Category: Dermatology | ||||||
| 02/12/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $25.00 | General |
| Category: Dermatology | ||||||
| 02/11/2024 | Incyte Corporation | OPZELURA (Drug) | Travel and Lodging | Cash or cash equivalent | $447.00 | General |
| Category: Dermatology | ||||||
| 02/11/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $140.00 | General |
| Category: Dermatology | ||||||
| 02/11/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $98.38 | General |
| Category: Dermatology | ||||||
| 02/02/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $4.21 | General |
| Category: Dermatology | ||||||
| 01/23/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $92.23 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Study to evaluate the efficacy and tolerability of a topical serum in femail subjects with mild to severe Melasma or post-inflammatory Hyperpigmentation | AbbVie Inc. | $136,811 | 1 |
| AN OPEN-LABEL PILOT STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY IN ADULT SUBJECTS WITH NON-SEGMENTAL FACIAL VITILIGO | Aclaris Therapeutics, Inc. | $10,248 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 449 | 1,239 | $252,090 | $96,998 |
| 2022 | 10 | 393 | 1,126 | $206,860 | $88,780 |
| 2021 | 12 | 365 | 1,090 | $191,495 | $84,948 |
| 2020 | 11 | 360 | 1,112 | $193,145 | $80,012 |
Total Patients
1,567
Total Services
4,567
Medicare Billing
$350,738
Procedure Codes
44
All Medicare Procedures & Services
44 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 96910 | Therapy procedure using ultraviolet radiation with tar or petroleum jelly application | Office | 2023 | 11 | 396 | $62,730 | $40,727 | 64.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 187 | 458 | $90,550 | $30,928 | 34.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 52 | 63 | $17,615 | $6,164 | 35.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 40 | 40 | $17,400 | $4,213 | 24.2% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 35 | 37 | $12,120 | $4,007 | 33.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 23 | 23 | $13,650 | $3,941 | 28.9% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 26 | 40 | $8,980 | $2,147 | 23.9% |
| 11901 | Injection into skin growth, more than 7 growths | Office | 2023 | 18 | 34 | $5,735 | $1,851 | 32.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 20 | 20 | $8,100 | $1,466 | 18.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 20 | 21 | $2,925 | $941.40 | 32.2% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 17 | 107 | $12,285 | $613.25 | 5.0% |
| 96910 | Therapy procedure using ultraviolet radiation with tar or petroleum jelly application | Office | 2022 | 14 | 329 | $47,705 | $34,274 | 71.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 171 | 432 | $75,600 | $30,632 | 40.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 44 | 59 | $15,045 | $6,196 | 41.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 24 | 24 | $12,600 | $3,836 | 30.4% |
| 11104 | Punch biopsy, first skin growth | Office | 2022 | 29 | 35 | $10,500 | $3,771 | 35.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 27 | 27 | $10,800 | $3,459 | 32.0% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 27 | 44 | $9,020 | $2,314 | 25.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 21 | 21 | $7,875 | $1,860 | 23.6% |
| 11901 | Injection into skin growth, more than 7 growths | Office | 2022 | 18 | 28 | $4,340 | $1,683 | 38.8% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 18 | 127 | $13,375 | $753.84 | 5.6% |
| 96910 | Skin application of tar and ultraviolet b or petrolatum and ultraviolet b | Office | 2021 | 15 | 385 | $55,825 | $41,145 | 73.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 158 | 389 | $68,075 | $26,695 | 39.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 34 | 40 | $10,200 | $3,792 | 37.2% |
| 11104 | Punch biopsy of single skin lesion | Office | 2021 | 21 | 24 | $7,200 | $2,678 | 37.2% |
About Dr. Pearl Grimes, MD
Dr. Pearl Grimes, MD is a Dermatology healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1790702751.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Pearl Grimes, MD has received a total of $358,500 in payments from pharmaceutical and medical device companies, with $22,208 received in 2024. These payments were reported across 155 transactions from 13 companies. The most common payment nature is "" ($147,058).
As a Medicare-enrolled provider, Grimes has provided services to 1,567 Medicare beneficiaries, totaling 4,567 services with total Medicare billing of $350,738. Data is available for 4 years (2020–2023), covering 44 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Los Angeles, CA
- Active Since 07/16/2006
- Last Updated 07/08/2007
- Taxonomy Code 207N00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1790702751
Products in Payments
- OPZELURA (Drug) $75,711
- TREMFYA (Drug) $6,075
- OLUMIANT (Drug) $4,000
- Recell (Device) $3,556
- AKLIEF (Drug) $1,575
- TALTZ (Drug) $761.66
- EUCRISA (Drug) $48.73
- DUPIXENT (Biological) $29.32
- ENSTILAR (Drug) $21.08
- ACCLARENT AERA (Device) $17.26
- DORYX (Drug) $10.96
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Los Angeles
Christopher Ho, Md, MD
Dermatology — Payments: $929,207
Dermatology $929,207
Dr. Howard Sofen, M.d, M.D
Dermatology — Payments: $654,301
Dermatology $654,301
Jennifer Hsiao, M.d, M.D
Dermatology — Payments: $400,325
Dermatology $400,325
Derek Jones, Md, MD
Dermatology — Payments: $316,086
Dermatology $316,086
Rebecca Fitzgerald, M.d, M.D
Dermatology — Payments: $281,818
Dermatology $281,818
Nada Elbuluk, Md, MD
Dermatology — Payments: $205,242
Dermatology $205,242